A Phase 1 Multicenter, Dose Escalation Study of CBT-501 in Subjects With Select Advanced or Relapsed/Recurrent Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Genolimzumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Liver cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors CBT Pharmaceuticals
- 30 Mar 2017 According to a CBT Pharmaceuticals media release, the first patient has been enrolled in this trial.
- 14 Mar 2017 Status changed from not yet recruiting to recruiting.
- 23 Feb 2017 According to a CBT Pharmaceuticals media release, this study will be initiated in the first half of 2017.